The value of CD23 expression as an additional marker in distinguishing mediastinal (Thymic) large B-cell lymphoma from Hodgkin Lymphoma

Mohamed E. Salama, M. Rajan Mariappan, Kedar Inamdar, Sheryl R. Tripp, Sherrie L. Perkins

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Mediastinal diffuse large B-cell lymphoma (Med-DLBCL) is a subtype of DLBCL that has morphologic and clinical similarities and phenotypic overlaps with classical Hodgkin lymphoma (CHL) involving the mediastinum. CD23 is a marker that has been previously reported in Med-DLBCI and is proposed in the differential diagnosis of M-DLBCL and CHL. A panel of immunostains, including CD45, CD20, CD3, CD30, CD15, CD21, and CD23 as well as Eber was performed on Med-DLBCL and 20CHL. 23/27 Med-DLBCL (85%) were positive for CD23 (membranous) CD30 was negative in 6 and positive in 21 cases. 18 CHL cases were negative for CD23 and only 2 showed rare scattered Reed-Sternberg cells with weak cytoplasmic CD23 staining. CD23 showed a sensitivity of 85% and positive predictive value of 92%. In conclusion CD23 is a useful marker in distinguishing Med-DLBCL and CHL in mediastinal biopsies and may be helpful as an adjunct to histomorphology and other markers in the diagnosis and appropriate clinical management of these lesions.

Original languageEnglish (US)
Pages (from-to)121-128
Number of pages8
JournalInternational Journal of Surgical Pathology
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2010

Keywords

  • CD23
  • Classical Hodgkin lymphoma
  • Mediastinal large cell lymphoma

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'The value of CD23 expression as an additional marker in distinguishing mediastinal (Thymic) large B-cell lymphoma from Hodgkin Lymphoma'. Together they form a unique fingerprint.

  • Cite this